Curaleaf Holdings, Inc.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Curaleaf Holdings, Inc. operates as a holding company with interest in medical and wellness cannabis operations. It operates through the Cannabis Operations and Non-Cannabis Operations segments. The Cannabis Operations segment includes the production and sale of cannabis via retail and wholesale channels. The Non-Cannabis Operations segment provides professional services including cultivation, processing and retail know-how and back office administration, intellectual property licensing, real estate leasing services and lending facilities to medical and adult-use cannabis licensees under management service agreements. The company was founded on November 13, 2014 and is headquartered in New York, NY.

The rescheduling of marijuana from a Schedule I to Schedule III drug in the United States would be transformative for the cannabis sector, CEOs of leading cannabis companies believe.  Last week, the Department of Health and Human Services (HHS) made a recommendation to the Drug Enforcement Administration (DEA) to re-classify marijuana as a lower-risk drug.

Marijuana rescheduling would be ‘life-changing event' for cannabis companies, CEOs say

Green Thumb Industries Inc.

New York state's largest medical-cannabis companies, which have been barred from wading into the adult-use market for more than two years, are saying they've waited long enough for licenses from the state.

Medical-cannabis companies blast New York for ‘clear course for failure' in state pot-business rollout

Tilray Brands

Cannabis stocks have floundered over the past several years. However, the momentum building within the global legalization movement has recently sparked a trend reversal.

3 Top Growth Stocks to Buy in September

Aurora Cannabis

Canopy Growth

Cronos Group

Innovative Industrial Properties

Chicago Atlantic Real Estate Finance

SNDL Inc.

Constellation Brands

Curaleaf Holdings Inc. OTCMKTS: CURLF,  Innovative Industrial Properties Inc. NYSE: IIPR and Tilray Inc. NASDAQ: TLRY were among cannabis stocks jumping higher after the Department of Health and Human Services recommended that marijuana no longer be classified as a Schedule 1 drug.

Will This New Development Mean A Big Rally In Cannabis Stocks?

Last month, the Department of Health and Human Services suggested easing regulations on marijuana use. The Drug Enforcement Agency has final say on that -- but its boss, President Joe Biden, now says he supports medical marijuana legalization.

Why Marijuana Stocks Keep Growing Higher Tuesday

OrganiGram Holdings Inc.

Trulieve Cannabis Corp.

Cannabis stocks continued to move higher following the Labor Day long weekend after the U.S. Department of Health and Human Services (HHS) last week recommended reclassifying marijuana as a lower-risk drug.

Cannabis stock rally continues on marijuana rescheduling hopes

Zero Proof's inaugural product offering, Squeeze, delivers fast-acting line of THC beverage enhancers in a sessionable and easy-to-use format NEW YORK , Sept. 5, 2023 /PRNewswire/ -- Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, today announced the launch of Zero Proof, a new brand of THC drinkables in fast-acting, sessionable and easy-to-use formats.

Curaleaf Expands Brand Portfolio With Launch of Zero Proof ™ Cannabis-Infused Drinkables

2 Marijuana Stocks To Watch In September 2023

Those looking for the best marijuana stocks to buy could be in luck. The level of volatile trading occurring in the market has led to a consistent decline in trading. Now most think when there is a drop in trading that it's always a negative. However, this is not the case in certain circumstances. No matter the sector when there is a drop in the trading this is often times seen as a buying opportunity. Right now many see cannabis as the investment of the future.

3 Marijuana Stocks To Watch Today 2023

Cannabis stocks are on track to finish the week higher boosted by the news that the U.S. Department of Health and Human Services (HHS) has recommended reclassifying marijuana as a lower-risk drug.

Cannabis stocks set to end week on a high following marijuana rescheduling recommendation

The recommendation is part of a larger marijuana reform plan announced by the Biden Administration last year.

Cannabis Stocks Surge After HHS Recommends Classifying Marijuana As Lower-Risk Drug

Amplify Alternative Harvest ETF

AdvisorShares Pure US Cannabis ETF

Global X Cannabis ETF

The move by the Drug Enforcement Administration to review the Schedule I classification for cannabis sparked a wave of speculation and mostly positive comments from Wall Street on Thursday, but many questions remain.

HHS recommendation to reschedule cannabis keeps pot stocks hot, but questions remain

Cannabis stocks are up on Thursday as investors in the market react to news marijuana may be downgraded from a Schedule I drug. According to insiders, a member of the Department of Health and Human Services is seeking a drop in the drug from Schedule I to Schedule III.

Why Are Cannabis Stocks TLRY, ACB, CGC, CURLF Up Today?

Shares of marijuana companies climbed as much as 14% in morning trading on Thursday after the Department of Health and Human Services recommended its reclassification as a lower-risk substance following an 11-month review.

Pot firms gain as US move to ease curbs boosts sentiment

The US government is reconsidering how it classifies marijuana and cannabis companies are in party mode. According to reports, the Department of Health and Human Services (HHS) has recommended reclassifying marijuana as a lower-risk Schedule III drug, from Schedule I, easing restrictions on businesses operating in the sector.

Cannabis stocks on fire as US health department calls for easing restrictions

Marijuana stocks could be next to see stronger momentum in the stock market. The level of volatile trading that has been occurring over the last year or so has hurt the confidence of investors. The fear is without any federal reform in place that regulations have the ability to halt the industry. However, with the amount of success the cannabis industry has seen it is doubtful that will happen. Nevertheless, the thoughts on investing in cannabis stocks have turned into a long-term game.

Top Marijuana Stocks For September Investing

The continued lack of legalization of marijuana at the federal level is preventing greater growth across the industry. That could change by the end of this year.

3 Cannabis Stocks Poised for Blazing-Hot Growth in 2024

The U.S. Department of Health and Human Services is recommending to the U.S. Drug Enforcement Administration that cannabis should be reclassified as a Schedule III controlled substance under U.S. law from Schedule I now, according to a report by Bloomberg. Cannabis stocks are rallying, with the AdviserShares Pure US Cannabis ETF MSOS, +18.76% up by nearly 33%, and the ETFMG Alternative Harvest ETF MJ, +10.27% up by 19.5%.

U.S. Dept. of Health and Human Services recommends re-scheduling cannabis, as stocks in the sector rally

Investing in cannabis stocks has seen a series of mistakes, including underestimating growth deceleration and overestimating synergies from M&A. Alan Brochstein and Julian Lin on why companies in the cannabis industry should be more aggressive in paying down debt to mitigate risk.

Cannabis Investing With Alan Brochstein & Julian Lin - REITs And Canadian LPs Over MSOs

With the chances of marijuana companies accessing the U.S. financial system higher than ever and cannabis stocks trading at lower valuations than ever before, now looks like an excellent time to seek out top-notch cannabis stocks to buy. Regarding access to the American financial system, Senate Majority Leader Chuck Schumer, a Democrat, appears to be working hard to enable the cannabis sector to obtain this much-needed change.

These Are the ONLY 3 Cannabis Stocks to Consider in August 2023

High Tide

Jazz Pharmaceuticals

I will attempt to assess and rank the relative growth potential of the separate competitors in the industry. The industry faces multiple catalysts and is trading near 52-week lows. The cannabis ETFs are full of cash burning companies, so I am forced to research my own basket of stocks.

Finding The Long-Term Winners In The Cannabis Sector, August 2023 Update

Cannabis stocks are far from creating sustainable values. There have been two instances when cannabis stocks have skyrocketed on hopes of robust growth and legalization in the last five years.

3 Millionaire-Maker Cannabis Stocks to Hold Through Thick and Thin

In Q3 2023, US marijuana stocks emerged as important stock market players, reflecting the fast-growing cannabis sector. The US cannabis sector has attracted attention for its profitable potential, with an astounding annual growth rate of 30% in 2023. In general, the future of the cannabis sector in the United States remains bright, thanks to rising legalization and altering societal attitudes.

Top US Marijuana Stocks to Watch in Q3 2023: Promising Investment Opportunities

Curaleaf Manchester is the Company's fourth dispensary in Connecticut to commence adult use sales NEW YORK , Aug. 21, 2023 /PRNewswire/ --  Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, today announced that has commenced adult use sales at its Manchester, Connecticut location. Located at 240 Buckland St, Manchester, CT 06042, Curaleaf Manchester is the Company's fourth dispensary in Connecticut to commence adult use sales.

Curaleaf Celebrates Launch of Adult Use Sales at Manchester, CT Dispensary

Marijuana legalization will solve problems for cannabis companies but it will also make some new ones. Timing the market can be a risky strategy for investors.

Waiting to Buy Marijuana Stocks After Legalization Could Be a Costly Mistake

News for Curaleaf Holdings, Inc. Stock (CURLF)